Tesamorelin
An FDA-approved GHRH analog for HIV-associated visceral fat—one of the few legitimate prescription GH-axis peptides in the U.S.
Back to all peptides
✨ real molecule sketch
See this name online?
Tesamorelin
Fitness peptides are often sold for “research use”—learn the compound before trusting a label.
Pharmacokinetic snapshot
Reference values from published sources—not prescribing or dosing advice. Cosmetic INCI peptides do not belong here; injectable and prescription contexts only.
- Half-life
- ~26 min
- Typical dose range
- 1–2 mg
- Common frequency
- Daily (FDA-approved for HIV lipodystrophy)
Source: DailyMed Egrifta
Structure (cute edition)
✨ real molecule sketch
This peptide is a short chain of about 4 amino acids—think of it as a tiny protein necklace on your label.
INCI: Tesamorelin · ~4 amino acids in our simplified view
FDA label data
Sourced from OpenFDA drug labels (public domain). Not medical advice.
Brand names: EGRIFTA SV, EGRIFTA WR
Manufacturer: Theratechnologies Inc.
Indications
1 INDICATIONS AND USAGE EGRIFTA SV is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Limitations of Use: Long-term cardiovascular safety of EGRIFTA SV has not been established. Consider risk/benefit of continuation of treatment in patients who have not had a reduction in visceral adipose tissue. EGRIFTA SV is not indicated for weight loss management as it has a weight neutral effect. There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking EGRIFTA SV. EGRIFTA SV is a growth hormone-re…
Research & public records
Counts and links from public databases (PubMed, ClinicalTrials.gov, Wikidata, NIH drug nomenclature). Educational only — not medical advice.
Knowledge base: pharmaceutical drug
PubMed: 93 indexed papers (search PubMed)
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol. · BMJ open
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. · Frontiers in endocrinology
- The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment. · eNeurologicalSci
- Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. · JBJS reviews
- Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists. · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
- Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. · International journal of molecular sciences
- Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model. · Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. · Sports medicine (Auckland, N.Z.)
Clinical trials: 25 studies on ClinicalTrials.gov (view search)
- Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue · WITHDRAWN
- Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients · COMPLETED
- Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese · COMPLETED
- The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment · COMPLETED
- Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) · RECRUITING
- Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA® · TERMINATED
- Effects of Growth Hormone Releasing Hormone in HIV · COMPLETED
- Egrifta Replacement and Sleep Disordered Breathing · WITHDRAWN
ChEMBL: TESAMORELIN · max phase 4.0
RxNorm names: tesamorelin 2 MG Injection [Egrifta]; tesamorelin 11.6 MG Injection [Egrifta] (RxNav)
DailyMed labels: 2 SPLs
What brands say it does
Tesamorelin is a stabilized GHRH analog that increases GH and IGF-1. It is approved (as Egrifta) to reduce excess abdominal fat in HIV lipodystrophy. Bodybuilders sometimes discuss it for fat redistribution, but that is off-label. Requires medical supervision and carries GH-related side-effect risks.
Where you’ll find it
Prescription specialty pharmacies and HIV metabolic clinics—not gray-market peptide sites.
Other names you might see
Egrifta
TH9507
Compare with similar peptides
Similar peptides
Educational only—not medical advice. Many compounds here are banned in sport and not FDA-approved for OTC use.